A BCL2 promoter polymorphism rs2279115 is not associated with BCL2 protein expression or patient survival in breast cancer patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2193-1801
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A BCL2 promoter polymorphism rs2279115 is not associated with BCL2 protein expression or patient survival in breast cancer patients ; volume:1 ; number:1 ; day:23 ; month:10 ; year:2012 ; pages:1-8 ; date:12.2012
SpringerPlus ; 1, Heft 1 (23.10.2012), 1-8, 12.2012
- Urheber
-
Searle, Claire J.
- Beteiligte Personen und Organisationen
-
Brock, Ian W.
Cross, Simon S.
Balasubramanian, Sabapathy P.
Reed, Malcolm W R.
Cox, Angela
SpringerLink (Online service)
- DOI
-
10.1186/2193-1801-1-38
- URN
-
urn:nbn:de:1111-201606107503
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Searle, Claire J.
- Brock, Ian W.
- Cross, Simon S.
- Balasubramanian, Sabapathy P.
- Reed, Malcolm W R.
- Cox, Angela
- SpringerLink (Online service)
Ähnliche Objekte (12)
BCL2 genotypes and prostate cancer survival
Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2
Bcl2 inhibition of mitochondrial DNA repair
CD23-positive, BCL2-Rearrangement-negative Keimzentrumslymphome
Survival of midbrain dopamine neurons depends on the Bcl2 factor Mcl1
The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia
Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement
Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer
GNA13 regulates BCL2 expression and the sensitivity of GCB-DLBCL cells to BCL2 inhibitors in a palmitoylation-dependent manner
Computational study on novel natural inhibitors targeting BCL2
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
Die Expression von BCL2 und CD95 im humanen Pankreaskarzinom
BCL2 genotypes and prostate cancer survival
Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2
Bcl2 inhibition of mitochondrial DNA repair
CD23-positive, BCL2-Rearrangement-negative Keimzentrumslymphome
Survival of midbrain dopamine neurons depends on the Bcl2 factor Mcl1
The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia
Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement
Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer
GNA13 regulates BCL2 expression and the sensitivity of GCB-DLBCL cells to BCL2 inhibitors in a palmitoylation-dependent manner
Computational study on novel natural inhibitors targeting BCL2
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
Die Expression von BCL2 und CD95 im humanen Pankreaskarzinom
BCL2 genotypes and prostate cancer survival
Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2
Bcl2 inhibition of mitochondrial DNA repair
CD23-positive, BCL2-Rearrangement-negative Keimzentrumslymphome
Survival of midbrain dopamine neurons depends on the Bcl2 factor Mcl1
The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia
Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement
Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer
GNA13 regulates BCL2 expression and the sensitivity of GCB-DLBCL cells to BCL2 inhibitors in a palmitoylation-dependent manner
Computational study on novel natural inhibitors targeting BCL2
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes